Johnson & Johnson has proposed a settlement of up to $5.5 billion to resolve approximately 76,000 lawsuits in the United States. These legal actions allege that the company's talcum powder products caused ovarian cancer.
The $5.5 billion gamble to clear 76,000 US claims
Johnson & Johnson is attempting to put a definitive end to a protracted legal battle by offering payments that would be distributed in 2027 and 2028. According to the report, the company has scheduled payments of roughly £2.26 billion for 2027, with further installments to follow the next year. While the company has set a headline figure of $5.5 billion, lawyers for the plaintiffs suggest the final cost could climb above £5.26 billion because the settlement lacks a hard cap.
Despite the massive financial offer, Johnson & Johnson continues to deny any wrongdoing. Erik Haas, the vice president of litigation for Johnson & Johnson, stated that the settlement is intended to allow the organization to refocus on its primary mission of creating life-saving medical devices and medicines. The company maintains that its talc-based products are safe and do not cause cancer.
Why a 95% approval rate is the critical hurdle for J&J
The proposed resolution is not a guaranteed exit. For the settlement to be finalized, legal firms representing 95% of the claims in US courts must accept the terms. This high threshold means that a small minority of determined law firms could potentially block the collective agreement, keeping the litigation active for thousands of claimants.
Chris Seeger ,a lawyer representing the claimants, has indicated that the deal would provide meaningful relief to victims who have spent years waiting for compensation.. However, the requirement for near-unanimous consent among legal representatives adds a layer of volatility to Johnson & Johnson's strategy to clear its balance sheet of these liabilities.
Kenvue's £1 billion liability risk in the UK High Court
While the US settlement offers a path to closure, it does not extend to international jurisdictions... In the United Kingdom, over 3,000 individuals have filed lawsuits in the High Court, alleging that baby powder used between 1965 and 2023 led to mesothelioma or ovarian cancer. These claims are directed at Kenvue, the consumer health spin-off from Johnson & Johnson that now manages liability for baby powder outside of North America.
The stakes in Britain are significant, with potential damages estimated at approximately £1 billion. Tom Longstaff, a partner at KP Law, has emphasized that the US settlement has no impact on the UK proceedings. A trial in the British courts is currently scheduled for February 2028, ensuring that the talc controversy will remain a legal fixture for several more years.
The 2020 shift to cornstarch and the global phase-out
The current legal crisis follows a broader corporate pivot in product formulation. in 2020, Johnson & Johnson reformulated its baby powder in the US market, replacing talc with cornstarch. This transition was expanded to a global scale by 2023, effectively ending the sale of talc-based baby powder worldwide.
This shift reflects a wider industry trend of moving away from talc due to the persistent risk of asbestos contamination . As reported, Kenvue maintains that its products were always compliant with regulatory standards and were backed by independent testing, yet the total abandonment of talc suggests a strategic decision to eliminate the primary source of these multi-billion dollar lawsuits.
The unresolved debate over asbestos contamination
A central point of contention that remains unverified is the allegation that Johnson & Johnson was aware of asbestos contamination in its talc but continued to sell the product. UK claimants specifically allege this prior knowledge, while Johnson & Johnson and Kenvue continue to assert that their products were asbestos-free.
Because the company denies the claims as meritless and cites studies supporting talc's safety, the truth of these contamination allegations likely rests on internal documents that will be scrutinized during the 2028 UK trial. Until then, the discrepancy between the company's safety assertions and the plaintiffs' claims of hidden contamination remains the core of the dispute.
Comments 0